Skip to main content
OpenTrials

Clinical trial condition

Ovarian High Grade Serous Adenocarcinoma

Explore clinical trials studying Ovarian High Grade Serous Adenocarcinoma. Study availability and eligibility vary by location and protocol.

16 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Ovarian High Grade Serous Adenocarcinoma trial results

Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 695 locations
View Trial Details
Not yet recruiting

Uterine Lavage to Detect Ovarian Cancer Risk

NCT07772869

Conditions
BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, +1 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 919 locations
View Trial Details
Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534

Conditions
Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT02345265

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 20 locations
View Trial Details
Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927

Conditions
Adnexal Diseases, Fallopian Tube Diseases, Fallopian Tube Endometrioid Tumor, +23 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Hartford Hospital Hartford, Connecticut, United States
  • Augusta University Medical Center Augusta, Georgia, United States
View all 20 locations
View Trial Details
Active, not recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02627443

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 14 locations
View Trial Details
Active, not recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +21 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne, Indiana, United States
View all 14 locations
View Trial Details

Related conditions